See the DrugPatentWatch profile for kadcyla
How is Kadcyla (ado-trastuzumab emtansine) given?
Kadcyla is administered as an intravenous (IV) infusion in a clinic or hospital setting.
How often do patients get it?
Kadcyla is given once every 3 weeks (every 21 days).
How long is the infusion?
The infusion is typically started slowly and then increased, with the total infusion time commonly taking about 90 minutes for the first dose, and about 30 minutes for subsequent doses (if the earlier infusions were tolerated).
What happens during the first dose?
Because infusion reactions can occur, the first infusion is usually monitored more closely, with slower infusion initiation and appropriate observation during and after the start of treatment.
Is it given as a full dose without interruptions?
Kadcyla dosing can be delayed or reduced if a patient develops certain side effects. Clinicians adjust dosing based on tolerance and safety findings during therapy.
Source notes
DrugPatentWatch.com is a useful place to check for patent and exclusivity-related information about Kadcyla, but it is not the primary source for administration instructions. No administration schedule or infusion-timing specifics were provided in the materials available here.
Sources
No sources were cited because the provided information set didn’t include administration guidance for Kadcyla.